Trial Profile
An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Gemcitabine; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jan 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2014.
- 16 Dec 2013 Planned end date changed from 1 Feb 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.